We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
Tracking stocks insiders are buying is always helpful. Tips for beating the market tend to come and go quickly, but this one has held up.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that The American Journal of Gastroenterology – the official journal of The A
Ironwood Pharmaceuticals (IRWD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Ironwood Pharmaceuticals, Inc. (IRWD) CEO Thomas McCourt on Q1 2021 Results - Earnings Call Transcript
Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations.

Recap: Ironwood Pharmaceuticals Q1 Earnings

07:20am, Thursday, 06'th May 2021
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 500.00% over the past year to $0.24, which beat
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. A media mogul was among the insiders making purchases this week.

7 Stocks With Significant Insider Buying

04:07pm, Tuesday, 09'th Mar 2021
There are many reasons an insider might sell. But there is only one reason for insider buying; insiders think the stock will trade higher.
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. A pair of chief executives and an executive board chair were among the insiders making pu
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, announced that management will be presenting at the following investor conferences: SVB Leerink
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.
Ironwood Pharmaceuticals, Inc.'s (IRWD) CEO Mark Mallon on Q4 2020 Results - Earnings Call Transcript
Ironwood (IRWD) delivered earnings and revenue surprises of 33.33% and 9.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE